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Background—5AMP-activated protein kinase (AMPK), a well-known regulator of cellular energy status, is also
implicated in ischemic preconditioning leading to cardioprotection. We hypothesized that AMPK is involved in
anesthetic-induced cardioprotection and that this activation is mediated by reactive oxygen species (ROS).
Methods and Results—Isolated Langendorff-perfused rat hearts were subjected to 35 minutes of global ischemia (I)
followed by 120 minutes of reperfusion (I/R). Hearts were assigned to a control group (Con) or a sevoflurane (Sevo)
group receiving 3 times 5-minute episodes of sevoflurane (2.5vol%) before I/R. Phosphorylation of both AMPK and
endothelial nitric oxide synthase (eNOS) were determined by Western blot analysis. Cardioprotection was assessed after
I/R from recovery of left ventricular pressure and from infarct size (triphenyltetrazolium chloride staining). In the
control group, ischemia resulted in a 2-fold increase in phosphorylation levels of AMPK (Con 0.130.01 versus Con-I
0.280.05, P0.05), which was sustained after 120 minutes of reperfusion (Con-I/R 0.260.02, P0.05). Sevoflurane
preconditioning had no affect on AMPK phosphorylation before ischemia (Sevo 0.120.03, P0.05), but almost
doubled the increase in AMPK phosphorylation relative to control after ischemia (Sevo-I 0.480.09, P0.05), an effect
that was sustained after reperfusion (Sevo-I/R 0.490.12, P0.05). The AMPK-inhibitor compound C (10 mol/L)
reduced the sevoflurane-mediated increase in phosphorylation of AMPK and its target eNOS and abolished
cardioprotection. The ROS-scavenger n-(2-mercaptopropionyl)-glycine (1 mmol/L) blunted the sevoflurane-mediated
increase in AMPK and eNOS phosphorylation and prevented cardioprotection.
Conclusions—Sevoflurane-induced AMPK activation protects the heart against ischemia and reperfusion injury and relies
on upstream production of ROS. (Circulation. 2009;120[suppl 1]:S10–S15.)
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The heart possesses intrinsic protective mechanismsagainst ischemia and reperfusion (I/R) injury, which are
induced by brief ischemic episodes and rely on protein kinase
C (PKC), glycogen synthase kinase 3 (GSK3), and on
production of reactive oxygen species (ROS).1 Volatile anes-
thetics, such as sevoflurane, exert cardioprotective properties
as well and operate via similar signaling cascades.2–4 For
instance, sevoflurane-induced production of ROS during the
preconditioning period is involved in cardioprotection,3
whereas sevoflurane preconditioning also reduces the exces-
sive production of ROS after I/R.5 The in vivo relevance of
these processes is demonstrated by De Hert et al, who showed
that sevoflurane improved cardiac function in patients during
coronary artery bypass surgery6 and in high-risk patients with
reduced cardiac function.7
5AMP-activated protein kinase (AMPK), an important
sensor and regulator of cellular energy status, is activated in
response to ischemic stress and is implicated in ischemic
preconditioning.8 In nonischemic hearts, AMPK is activated
by hydrogen peroxide (H2O2)9 and peroxynitrite (ONOO).10
Currently, it is unknown whether AMPK plays a role in
volatile anesthetics-induced cardioprotection.
Accordingly, we hypothesize that AMPK activation is
involved in anesthetic-induced cardioprotective signaling and
that this activation requires production of ROS. Elucidation
of the involvement of AMPK in anesthetic-induced cardio-
protective signaling may have important implications for the
development of clinical cardioprotective strategies, in partic-
ular during diabetes mellitus, where intrinsic AMPK-
dependent signaling is depressed.8
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To test our hypothesis we determined, in isolated
Langendorff-perfused rat hearts, the effect of sevoflurane on
phosphorylation of AMPK before ischemia, after ischemia,
and after reperfusion, as well as myocardial recovery and
infarct size after reperfusion. The functional contribution of
AMPK was assessed with a specific AMPK-inhibitor, and a
ROS-scavenger was used to assess the involvement of ROS.
Methods
An expanded version of Methods is provided in the Online
Data Supplement.
Animals and Experimental Set-Up
This study was performed in accordance with the guidelines of the
Institutional Animal Care and Use Committee of the VU University
Medical Center (VUMC), which conforms to the Guide for the Care
and Use of Laboratory Animals (NIH Publication No. 85-23, revised
1996). Male Wistar rats (n116, 250 to 400g; Harlan, The Nether-
lands) were anesthetized with pentobarbital (80 mg/kg, intraperito-
neal). Subsequently, the heart was rapidly excised and mounted in a
Langendorff set-up. Left ventricular (LV) pressures were measured
with a balloon inserted in the LV to determine functional recovery.
Experimental Protocol and Assays
To determine whether sevoflurane induces AMPK phosphorylation,
hearts were assigned to 2 groups: (1) Control (Con) group: no
preconditioning; (2) Sevoflurane (Sevo) group: preconditioning by
application of 3 times 5-minute episodes of sevoflurane (2.5vol%)
separated by 5 minutes of washout. Hearts from both groups were
frozen in liquid nitrogen immediately before ischemia, immediately
after 35 minutes of global ischemia (I), or after 35 minutes of global
ischemia followed by 120 minutes of reperfusion (I/R).
The contribution of sevoflurane-induced activation of AMPK and
the involvement of ROS to the improved myocardial recovery and
reduced infarct size were investigated by subsequently assigning
hearts of the control and sevoflurane group to subgroups identified
by the following inhibitors: (1) reversible AMPK inhibitor com-
pound C (CC, 10 and 1 mol/L), (2) ROS-scavenger n-(2-
mercaptopropionyl)-glycine (MPG, 1 mmol/L), (3) both MPG
(1 mmol/L) and CC (10 mol/L), and (4) NOS-inhibitor N-nitro-
L-arginine (L-NA, 0.1 mmol/L).
Recovery of LV pressures was determined, and infarct size was
assessed from triphenyltetrazolium chloride (TTC)-stained sec-
tions. Western blot analysis of LV apex samples was used for
determination of AMPK phosphorylation with an antibody
against phospho-AMPK at Thr172. AMPK activity was deter-
mined by measuring eNOS phosphorylation with an antibody
against phospho-eNOS at Ser1177.
Statistical Analysis
Levels of AMPK phosphorylation between the control and sevoflu-
rane group at 3 different time points (before ischemia, after ischemia,
after I/R) were obtained in different hearts and therefore analyzed
using 2-way ANOVA. Differences in AMPK and eNOS phosphor-
ylation, recovery of cardiac function (Pdeveloped, Pdiastolic, and dP/dt)
and infarct size between the control and sevoflurane groups with and
without CC were also analyzed with 2-way ANOVA, whereas the
effects of MPG and the combination of MPGCC were analyzed
with multiple ANOVA. The interaction term indicated whether the
effect of the inhibitor was different between the control and
sevoflurane group. A Bonferroni post hoc test was used to assess the
effect of the inhibitor within the control and sevoflurane group. A
value of P0.05 was considered significant. All data are expressed
as meansSEM.
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Figure 1. Sevoflurane enhances the is-
chemia-induced increase in AMPK phos-
phorylation, which is inhibited by the
AMPK-inhibitor compound C. A, Exam-
ples and averaged values of phosphoryla-
tion levels of AMPK at Thr172 in left ven-
tricular tissue in the control (Con) and
sevoflurane (Sevo) group before ischemia,
after 35 minutes of ischemia (I), and after
ischemia and 120 minutes of reperfusion
(I/R). The increase in AMPK-phosphoryla-
tion after I/R and I were enhanced in the
Sevo group compared to control group.
Values are expressed as meansSEM,
n6 per group, #P0.05 Sevo vs Control,
*P0.05 vs preischemia (post hoc). B,
Examples and averaged values of the
phosphorylation levels of AMPK, and
eNOS at Ser1177, in the absence and pres-
ence of AMPK-inhibitor compound C (CC,
10 mol/L). The 2-way ANOVA (interaction)
revealed that the effect of CC in the control
and sevoflurane group differed both for
AMPK and eNOS phosphorylation. The
sevoflurane-induced increase in AMPK and
eNOS phosphorylation after I/R was nor-
malized to control values by CC. Values are
expressed as meansSEM, n6 per
group, #P0.05 Sevo vs Control, *P0.05
CC vs non-CC (post hoc).
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Results
Sevoflurane Enhances the Ischemia-Induced
Increase in AMPK-Phosphorylation
In Figure 1A are shown representative examples and aver-
aged values of the phosphorylation levels of AMPK at
Thr172 in LV cardiac tissue of the control and sevoflurane
group, before ischemia, after ischemia, and after ischemia and
reperfusion. In the control group, 35 minutes of ischemia
resulted in an almost 2-fold increase in AMPK phosphoryla-
tion, an effect that was sustained after reperfusion. Before
ischemia, sevoflurane preconditioning had no effect on phos-
phorylation levels of AMPK. However, after ischemia,
sevoflurane preconditioning resulted in an almost 4-fold
increase in AMPK-phosphorylation relative to the control
group before ischemia, which was sustained after reperfusion.
This implies a 2-fold increase of AMPK phosphorylation by
sevoflurane preconditioning during ischemia.
AMPK Inhibition Blocks Sevoflurane-Induced
Increase in AMPK Phosphorylation and Activity
Figure 1B shows that the sevoflurane-induced increase in
AMPK phosphorylation after I/R was blocked by addition of
10 mol/L of the AMPK-inhibitor compound C (CC),
whereas in the Con I/R group, the levels of phosphorylation
of AMPK remained unaffected, although a trend to increased
levels existed. Addition of a lower dose (1 mol/L) of CC
had a similar effect (data not shown). The phosphorylation of
eNOS, a well-known target of AMPK and an index of its
activity, was increased in the Sevo I/R group compared to
control I/R group. The AMPK-inhibitor CC (10 mol/L) abol-
ished the sevoflurane-induced increase in eNOS phosphoryla-
tion after I/R. This indicates that AMPK-phosphorylation and its
activity were blocked. In addition, the NOS inhibitor L-NA
(0.1 mmol/L) also abolished the sevoflurane-induced increase in
eNOS phosphorylation after I/R (Con I/R L-NA: 0.220.04%
versus Sevo I/R L-NA: 0.280.05%, n5).
Sevoflurane-Induced AMPK Activation
Contributes to Cardioprotection
Anesthetic preconditioning with sevoflurane was evident
after I/R from an increased recovery of Pdeveloped anddP/dtmax
compared to controls (Figure 2A, n8). Pdiastolic values were
not different between groups after I/R. This sevoflurane-
induced improved functional cardiac recovery was abolished
by addition of 10 mol/L of the AMPK inhibitor CC (Figure
2A, n8). A lower concentration of CC (1 mol/L) also
blocked the sevoflurane-induced improved functional recov-
ery of Pdeveloped (Con I/R CC: 433% versus Sevo I/R CC:
475%, n5). In addition, the NOS inhibitor L-NA also
blocked the sevoflurane-induced improved functional recov-
ery (Con I/R L-NA: 37.44% versus Sevo I/R L-NA:
43.15%, n5). In time control experiments, without I/R,
the LV Pdeveloped at the end of the experiment (200 minutes)
amounted to approximately 80% of the value before ische-
mia (Figure 2A).
Figure 2. Contribution of sevoflurane-induced
AMPK activation to cardioprotection A, Examples
of left ventricular pressure (LVP) tracing during a
contraction and averaged data of LV Pdiastolic,
recovery of Pdeveloped and recovery of dP/dtmax in
isolated rat hearts in the control (Con) and sevoflu-
rane (Sevo) group after ischemia and reperfusion
(I/R) in the presence of AMPK-inhibitor compound
C (CC, 10 mol/L) and in time control groups. B,
Examples and averaged data of infarct size deter-
mined with TTC staining in isolated rat hearts in
control and sevoflurane groups after I/R in the
presence of CC. Two-way ANOVA revealed that
preconditioning with 2.5vol% sevoflurane resulted
in a significant increased recovery of Pdeveloped and
a reduced infarct size compared to controls. The
interaction in the 2-way ANOVA revealed that this
effect was abolished by CC. Values are expressed
as meansSEM, n8 per group, #P0.05 Sevo
vs Control, *P0.05 CC vs no-CC (post hoc).
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The analysis of the TTC-stained heart slices shown in
Figure 2B revealed that sevoflurane preconditioning substan-
tially reduced infarct size after I/R compared to controls
(n8). The sevoflurane-induced reduction in infarct size was
blocked by AMPK inhibitor CC at the high (10 mol/L;
Figure 2B, n8), as well as the lower (1 mol/L) concen-
tration (Infarct size: Con I/R CC: 234% versus Sevo I/R
CC: 223%, n5). In control hearts CC decreased infarct
size (Figure 2B). In addition, the NOS inhibitor L-NA
(0.1 mmol/L) also blocked the sevoflurane-induced reduction
in infarct size (Con I/R L-NA 284% versus Sevo I/R L-NA
264%, n5).
In the time control group, without I/R, myocardial damage
was only 1.60.8% (n8). In additional experiments (n3),
we found that DMSO, used as vehicle for dissolving CC, did
not affect the functional recovery after I/R (Pdeveloped: 446%),
nor did it reduce infarct size (304%).
Sevoflurane-Induced AMPK Activation Relies on
Production of ROS
Scavenging of ROS by addition of 1 mmol/L MPG during
sevoflurane preconditioning (n5) reduced the phosphoryla-
tion levels of AMPK (Figure 3A) and eNOS (Figure 3B) after
I/R. This was accompanied by blunting of functional recovery
(Figure 3C) and an increased infarct size (Figure 3D). In the
control group, without sevoflurane, no effects of MPG on
AMPK or eNOS phosphorylation, functional cardiac recov-
ery, and infarct size were observed (n5). In addition, the
combination of ROS scavenging (MPG) with AMPK inhibi-
tion (CC) resulted in phosphorylation levels of AMPK and
eNOS (Figure 3A and 3B) that were not different between
control and sevoflurane groups (both n5) and that were
equivalent to the levels found with either inhibitor alone.
Similar results were found for functional recovery (Figure
3C) and the infarct size (Figure 3D).
Discussion
The main finding of this study is that sevoflurane pretreat-
ment enhances AMPK activation during ischemia. This
activation results in improved myocardial recovery and re-
duced infarct size, as became apparent from the experiments
in which the AMPK-inhibitor compound C was used. In
addition, ROS scavenging during sevoflurane precondition-
ing blunted AMPK activation and abolished cardioprotection.
This indicates that sevoflurane-induced cardioprotection is
mediated via ROS-dependent activation of AMPK. Our study
demonstrates for the first time a direct link between AMPK
activation and the production of ROS in anesthetic-induced
cardioprotection.
The present study clearly shows that sevoflurane precon-
ditioning enhances the increase in AMPK phosphorylation
after ischemia, as well as after reperfusion. Although sevoflu-
rane did not immediately activate AMPK (Figure 1A), it
apparently primed the myocardium and doubled the increase
in AMPK phosphorylation observed after ischemia, which
persisted after reperfusion. This suggests that the ischemic
conditions are necessary to activate AMPK. Phosphorylation
of eNOS (Figure 1B), a well-known target of AMPK in
cardioprotective signaling,11 was increased as well, indicating
that changes in AMPK phosphorylation reflect changes in
AMPK activity. The sevoflurane-induced increase in AMPK
and eNOS phosphorylation was blunted by the AMPK-inhibitor
compound C. Compound C, as well as NOS inhibitor L-NA,
abolished the effects of sevoflurane on myocardial recovery and
infarct size, indicating that the sevoflurane-induced increased in
phosphorylation of AMPK and eNOS during ischemia are
functionally related to the cardioprotection.
Figure 3. Sevoflurane-induced AMPK activation
relies on production of ROS. Phosphorylation of
AMPK (A), phosphorylation of eNOS (B), myocar-
dial function (C), and infarct size (D) in control
(Con) and sevoflurane (Sevo) groups after ischemia
and reperfusion (I/R) in the presence of ROS-
scavenger MPG (1 mmol/L) and in the presence of
MPG and AMPK inhibitor compound C (CC,
10 mol/L). Multiple ANOVA revealed that MPG
reduced the sevoflurane-induced increase in
AMPK and eNOS phosphorylation, and abolished
sevoflurane-induced protective effects on myocar-
dial function and infarct size. No additional effects
of CC on the effects of MPG were found. Values
are expressed as meansSEM, n5 per group,
#P0.05 Sevo vs Control, *P0.05 MPG (CC) vs
non-MPG (-CC).
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In our control hearts compound C decreased infarct size,
which was accompanied by a trend to increased levels of
AMPK phosphorylation. Khaliulin et al12 noted in isolated rat
hearts that compound C enhanced cardioprotection induced
by temperature preconditioning and suggested that this para-
doxical effect of compound C might be related to altering the
balance between the beneficial and detrimental AMPK acti-
vation during I/R.13 The ischemia-induced AMPK activation
has the potential to increase myocardial energy supply by
glycolysis during ischemia and by glucose uptake during
reperfusion, thereby exerting a cardioprotective effect. How-
ever, AMPK activation can also stimulate fatty acid oxida-
tion, which can increase proton production and decrease
cardiac efficiency by concomitant inhibition of glucose oxi-
dation.13 These dual effects of AMPK on metabolic path-
ways, ion channels, protein synthesis, and cellular function
reflect its complex role during I/R. Our results show that
inhibition of ROS with MPG completely abolished the
sevoflurane-induced AMPK phosphorylation as well as car-
dioprotection. Hence, our results indicate that the additional
activation of AMPK by sevoflurane during ischemia is
beneficial as it protects against I/R injury. The absence of an
effect of MPG on AMPK phosphorylation and infarct size in
control hearts illustrates the complex role of AMPK during
I/R-injury.
How does sevoflurane enhance AMPK activation during
ischemia? During severe ischemia, intracellular ATP levels
drop, resulting in a substantial rise of the intracellular concen-
tration of 5-AMP in the heart, which will lead to AMPK
activation.14 Sevoflurane does not influence intracellular 5-
AMP levels in the heart, and no effects of sevoflurane were
found on intracellular myocardial ATP levels.15 Thus, alternative
mechanisms of AMPK activation should be considered.
The present study shows that the ROS-scavenger MPG
blunted the sevoflurane-induced enhanced AMPK activation
after I/R and that this was accompanied by an inhibition of
cardioprotection. MPG was applied during the precondition-
ing period, thus before the ischemic period when AMPK
activation took place. This indicates that sevoflurane-induced
AMPK activation is ROS-dependent. In addition, combining
ROS scavenging with AMPK inhibition did not result in an
additional effect on AMPK activation or cardioprotection,
indicating that the production of ROS is upstream of AMPK
activation in the same signaling pathway. MPG scavenges
hydroxyl radicals and ONOO but not H2O2 and superox-
ide.16 Moreover, ONOO reduced myocardial infarct size in
cats after I/R.17 These data, in combination with previous
observations from our laboratory showing that MPG is able to
inhibit the sevoflurane-induced ONOO modification of ty-
rosine residues,3 indicate that ONOO is the most likely
mediator for sevoflurane-induced ROS-dependent activation
of AMPK. The excessive ROS production during reperfusion
is detrimental for the heart,18 whereas small amounts of ROS
generated during preconditioning prove to be beneficial,5 as
also indicated by the present study.
Several other upstream factors, such as the tumor suppres-
sor protein LKB1, the calcium/calmodulin-dependent kinase
kinase (CaMKK)-,19 or the kinase H11K,20 are able to
activate AMPK. Cardiac AMPK activation was also linked to
activation of PKC and inhibition of GSK3.20,21 Volatile
anesthetics, such as sevoflurane, isoflurane, and desflurane,
also influence these kinases.2–4,22–24 For instance, activation
of different isoforms of PKC, which was preceded by ROS
production, and extracellular signal-regulated kinase 1/2
(ERK1/2) have been demonstrated in volatile anesthetic-induced
cardioprotective signaling.3,22,23 In addition, isoflurane pre- and
postconditioning was linked to activation of phosphatidylinositol
3-kinase inhibitor (PI3K)24 and GSK3.4 Our experiments
clearly indicate that sevoflurane-preconditioning alters ROS
production, but future experiments will be needed to elucidate
how these kinases relate to AMPK-dependent cardioprotective
signaling.
The isolated Langendorff perfused heart preparation in
present study was chosen to examine the underlying cardiac
mechanism of sevoflurane cardioprotection under controlled
ex vivo conditions to exclude possible confounding systemic
hemodynamics and humoral effects of sevoflurane and the
inhibitors. Caution should be exerted when extrapolating
these findings to the in vivo situation, although the intracel-
lular mechanism revealed most likely is important for anes-
thetic preconditioning in patients.
Conclusion
Sevoflurane-induced AMPK activation protects the heart against
ischemia and reperfusion injury and relies on upstream produc-
tion of ROS. Therefore, the present study indicates that AMPK
is not only a key regulator of energy status, but also plays a
pivotal role in anesthetic cardioprotection.
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